ArticleWorld journal of nuclear medicine2025
A Normalized Spot-Sample Estimation of α-1 Antitrypsin Clearance: The Search for a Simpler Test in Protein Losing Enteropathy.
Article in World journal of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Protein losing enteropathy (PLE) is usually a diagnosis of exclusion, which requires cumbersome tests to confirm. In the quest for a simpler diagnostic test, we hypothesized that a spot stool sample estimation of α-1 antitrypsin will be sufficient to make a diagnosis of PLE, if we control for serum α-1 antitrypsin concentration and degree of stool dilution. Materials and Methods: Consecutive patients with a clinical suspicion of PLE and who had been advised a scintigraphy study were recruited after getting informed consent. The study excluded patients less than 1 year of age, pregnant women, and those with a clinical suspicion of chronic pancreatitis. Serum α-1 antitrypsin, spot stool α-1 antitrypsin, and stool elastase was assessed in all the patients. The diagnostic value of the index test was estimated from the patients with positive scintigraphy scan compared with a negative scan, expressed as sensitivity and specificity and the area under the receiver operating characteristic curve (AUROC). Result: A total of 33 patients underwent scintigraphy with a clinical suspicion of PLE. Twenty patients (60%) showed tracer activity in the gut suggestive of PLE. Spot stool α-1 antitrypsin below 0.26 mg/g had a sensitivity of 100% to rule out PLE; however, the specificity was only 46%. Spot stool α-1 antitrypsin/(serum α-1 antitrypsin * elastase) ratio performed similar to spot stool α-1 antitrypsin as a diagnostic test (AUROC: 0.814 [0.61-1.0] vs. 0.796 [0.54-1.0]). Conclusion: Random stool antitrypsin is a sensitive test for diagnosing PLE; however, it lacks specificity. Spot stool α-1 antitrypsin/(serum α-1 antitrypsin * stool elastase) does not provide any additional value in the diagnosis of this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.